Claims for Patent: 11,235,168

Summary for Patent: 11,235,168

Title:	Method of photodynamic therapy (PDT) for bladder cancer
Abstract:	This invention relates to a method of photodynamic therapy (PDT) for bladder cancer and its use as an adjuvant or neoadjuvant therapy in the treatment of bladder cancer. The invention provides a composition comprising hexyl 5-ALA ester (HAL) or a pharmaceutically acceptable salt thereof for use in a method of photodynamic therapy for bladder cancer, wherein said composition is instilled into the bladder of a patient in need of such treatment and the inside of said bladder is exposed to blue light having a fluence rate of 1.5 to 12.5 mW/cm2.
Inventor(s):	Hestdal; Kjetil (Oslo, NO), Godal; Aslak (Oslo, NO)
Assignee:	PHOTOCURE ASA (Oslo, NO)
Application Number:	16/063,142
Patent Claims:	1. A method of photodynamic therapy for bladder cancer comprising the instillation into the bladder of a patient in need of such treatment of a composition in the form of a solution of 2 mg/ml hexyl 5-ALA ester (HAL) hydrochloride in an aqueous buffer comprising disodium phosphate dehydrate, potassium dihydrogen phosphate, sodium chloride, hydrochloric acid, sodium hydroxide and water and exposing the inside of said bladder to blue light having a fluence rate of 1.5 to 12.5 mW/cm.sup.2 and wherein the blue light is provided at a light dose of 0.2 to 15.0 J/cm.sup.2. 2. The method according to claim 1, wherein the inside of the bladder is exposed to blue light having a fluence rate of 2.5 to 7.0 mW/cm.sup.2. 3. The method according to claim 2, wherein the blue light is provided at a light dose of 0.3 to 8.0 J/cm.sup.2. 4. The method according to claim 1, wherein the blue light is provided at a light dose of 0.3 to 8.0 J/cm.sup.2. 5. The method according to claim 1, wherein the inside of said bladder is further exposed to white light having a fluence rate of 3.0 to 22.0 mW/cm.sup.2. 6. The method according to claim 5, wherein said white light is provided at a light dose of 0.4 to 26.5 J/cm.sup.2. 7. The method according to claim 5, wherein said inside of the bladder is exposed to white light having a fluence rate of 5.0 to 12.5 mW/cm.sup.2. 8. The method according to claim 5, wherein said white light is provided at a light dose of 0.6 to 15.0 J/cm.sup.2. 9. The method according to claim 8, wherein said white light is provided at a light dose of 0.6 to 15.0 J/cm.sup.2. 10. The method according to claim 5, wherein said inside of the bladder is first exposed to white light and then to blue light. 11. The method according to claim 5, wherein a blue-light cystoscope is used as a light source to provide said blue light and said white light. 12. The method according to claim 5, wherein the inside of the bladder is exposed to blue light and white light for a period of 2 to 20 minutes. 13. The method according to claim 5, wherein said method of photodynamic therapy is used as adjuvant therapy in the treatment of bladder cancer. 14. The method according to claim 13, wherein said bladder cancer is NMIBC and said method of photodynamic therapy is simultaneously carried out with a transurethral resection of NMIBC. 15. The method according to claim 13, wherein said bladder cancer is NMIBC and said method of photodynamic therapy is carried in a patient having undergone transurethral resection of NMIBC. 16. The method according to claim 13, wherein said method of photodynamic therapy replaces or partially replaces other adjuvant therapies. 17. The method according to claim 16, wherein said other adjuvant therapies are chemotherapy and/or immunotherapy. 18. The method according to claim 17, wherein said other adjuvant therapy is BCG treatment. 19. The method according to claim 5, wherein said method of photodynamic therapy is carried out in BCG refractory patients. 20. The method according claim 5, wherein said method of photodynamic therapy is used as neoadjuvant therapy in a method of treating bladder cancer. 21. The method according to claim 20, wherein said bladder cancer is MIBC. 22. The method according to claim 1, wherein said composition is an aqueous solution of HAL. 23. The method according to claim 22, wherein said composition is a solution of HAL in an aqueous buffer. 24. The method according to claim 22, wherein said composition is a solution of HAL in a phosphate buffer. 25. The method according to claim 22, wherein the pH of said composition is in the range of 4.5 to 7.5. 26. The method according to claim 1, wherein a blue-light cystoscope is used as a light source to provide said blue light. 27. The method according to claim 26, wherein said blue-light cystoscope is a commercially available blue-light cystoscope. 28. The method according to claim 1, wherein the inside of the bladder is exposed to blue light for a period of 2 to 20 minutes. 29. The method according to claim 1, wherein said method of photodynamic therapy is used as adjuvant therapy in the treatment of bladder cancer. 30. The method according to claim 29, wherein said bladder cancer is NMIBC and said method of photodynamic therapy is simultaneously carried out with a transurethral resection of NMIBC. 31. The method according to claim 29, wherein said bladder cancer is NMIBC and said method of photodynamic therapy is carried in a patient having undergone transurethral resection of NMIBC. 32. The method according to claim 29, wherein said method of photodynamic therapy replaces or partially replaces other adjuvant therapies. 33. The method according to claim 32, wherein said other adjuvant therapies are chemotherapy and/or immunotherapy. 34. The method according to claim 33, wherein said other adjuvant therapy is BCG treatment. 35. The method according to claim 1, wherein said method of photodynamic therapy is carried out in BCG refractory patients. 36. The method according claim 1, wherein said method of photodynamic therapy is used as neoadjuvant therapy in a method of treating bladder cancer. 37. The method according to claim 36, wherein said bladder cancer is MIBC.